Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
microtubule-associated protein, RP/EB family, member 1a
mapre1a
Official Full Name
microtubule-associated protein, RP/EB family, member 1a
Organism
Danio rerio
Gene ID
334135
Background
Predicted to enable microtubule plus-end binding activity. Predicted to be involved in protein localization to microtubule; regulation of microtubule polymerization or depolymerization; and spindle assembly. Predicted to act upstream of or within cell division. Predicted to be located in centrosome; microtubule; and spindle pole. Predicted to be active in microtubule cytoskeleton. Orthologous to human MAPRE1 (microtubule associated protein RP/EB family member 1). [provided by Alliance of Genome Resources, Feb 2025]